Brain structural and clinical changes after first episode psychosis: Focus on cannabinoid receptor 1 polymorphisms

Psychiatry Research - Neuroimaging

Volumn 233, Issue 2, 2015, Pages 112-119

  Suárez Pinilla, Paula ^a,b   Roiz Santiañez, Roberto ^a,b   Ortiz García de la Foz, Víctor ^a,b   Guest, Paul C ^c   Ayesa Arriola, Rosa ^a,b   Córdova Palomera, Aldo ^b,d   Tordesillas Gutierrez, Diana ^e   Crespo Facorro, Benedicto ^a,b  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF BARCELONA   (Spain)

^e Neuroimaging Unit Technological Facilities IDIVAL   (Spain)

Author keywords

Biological marker; CNR1 protein; Endophenotypes; Longitudinal studies; Magnetic resonance imaging; Neuroimaging; Schizophrenia

Indexed keywords

CANNABINOID RECEPTOR; CANNABINOID RECEPTOR 1; UNCLASSIFIED DRUG; CANNABINOID; CANNABINOID 1 RECEPTOR;

ADULT; ALLELE; ARTICLE; BODY MASS; BRAIN REGION; BRAIN SIZE; CANNABIS SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; BRAIN; GENETICS; PATHOLOGY; PATHOPHYSIOLOGY; SCHIZOPHRENIA;

ADULT; BRAIN; CANNABINOIDS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOTIC DISORDERS; RECEPTOR, CANNABINOID, CB1; SCHIZOPHRENIA;

EID: 84938747776     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2015.05.005     Document Type: Article

References (74)

1. Addington D., Addington J., Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary depression scale. Br. J. Psychiatry 1993, 163(Suppl. 22):S39-S44.
2. Akaike H. A new look at the statistical model identification. IEEE Trans. Autom. Control 1974, CA19:716-723.
3. Akaike H. Data analysis by statistical models. No To Hattatsu 1992, 24(2):127-133.
4. Andreasen N.C. Scale for the Assessment of Negative Symptoms (SANS) 1984, Department of Psychiatry, College of Medicine, University of Iowa, Iowa City.
5. Andreasen N.C. Scale for the Assessment of Positive Symptoms 1984, Department of Psychiatry, College of Medicine, University of Iowa, Iowa City.
6. Andreasen N.C., Cohen G., Harris G., Cizadlo T., Parkkinen J., Rezai K., Swayze V.W. Image processing for the study of brain structure and function: problems and programs. J. Neuropsychiatry. Clin. Neurosci. 1992, 4(2):125-133.
7. Andreasen N.C., Pressler M., Nopoulos P., Miller D., Ho B.C. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry 2010, 67(3):255-262.
8. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Br. Med. J. 2002, 325(7374):1212-1213.
9. Benzinou M., Chevre J.C., Ward K.J., Lecoeur C., Dina C., Lobbens S., Durand E., Delplanque J., Horber F.F., Heude B., Balkau B., Borch-Johnsen K., Jorgensen T., Hansen T., Pedersen O., Meyre D., Froguel P. Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. Hum. Mol. Genet. 2008, 17(13):1916-1921.
10. Beveridge N.J., Tooney P.A., Carroll A.P., Gardiner E., Bowden N., Scott R.J., Tran N., Dedova I., Cairns M.J. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum. Mol. Genet. 2008, 17(8):1156-1168.
11. Brown J.A., Horvath S., Garbett K.A., Schmidt M.J., Everheart M., Gellert L., Ebert P., Mirnics K. The role of cannabinoid 1 receptor expressing interneurons in behavior. Neurobiol. Dis. 2014, 63:210-221.
12. Busse S., Busse M., Schiltz K., Bielau H., Gos T., Brisch R., Mawrin C., Schmitt A., Jordan W., Muller U.J., Bernstein H.G., Bogerts B., Steiner J. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations?. Brain Behav Immun. 2012, 26(8):1273-1279.
13. Cannon T.D., Kaprio J., Lonnqvist J., Huttunen M., Koskenvuo M. The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study. Arch. Gen. Psychiatry 1998, 55(1):67-74.
14. Ceccarini J., De Hert M., van Winkel R., Koethe D., Bormans G., Leweke M., Peuskens J., Van Laere K. In vivo PET imaging of cerebrak type 1 cannabinoid receptor availability in patients with schizophrenia. Schizophr. Res. 2010, 117(2-3):170.
15. Costa M., Squassina A., Congiu D., Chillotti C., Niola P., Galderisi S., Pistis M., Del Zompo M. Investigation of endocannabinoid system genes suggests association between peroxisome proliferator activator receptor-alpha gene (PPARA) and schizophrenia. Eur. Neuropsychopharmacol. 2013, 23(7):749-759.
16. Cousijn J., Wiers R.W., Ridderinkhof K.R., van den Brink W., Veltman D.J., Goudriaan A.E. Grey matter alterations associated with cannabis use: results of a VBM study in heavy cannabis users and healthy controls. Neuroimage 2012, 59(4):3845-3851.
17. de Luis D.A., Ovalle H.F., Soto G.D., Izaola O., de la Fuente B., Romero E. Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2. J. Investig. Med. 2014, 62(2):324-327.
18. Dean B., Sundram S., Bradbury R., Scarr E., Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001, 103(1):9-15.
19. Dinu I.R., Popa S., Bicu M., Mota E., Mota M. The implication of CNR1 gene[U+05F3]s polymorphisms in the modulation of endocannabinoid system effects. Rom. J. Intern. Med. 2009, 47(1):9-18.
20. Eggan S.M., Hashimoto T., Lewis D.A. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch. Gen. Psychiatry 2008, 65(7):772-784.
21. Eggan S.M., Lazarus M.S., Stoyak S.R., Volk D.W., Glausier J.R., Huang Z.J., Lewis D.A. Cortical glutamic acid decarboxylase 67 deficiency results in lower cannabinoid 1 receptor messenger RNA expression: implications for schizophrenia. Biol. Psychiatry 2012, 71(2):114-119.
22. Ehlers C.L., Slutske W.S., Lind P.A., Wilhelmsen K.C. Association between single nucleotide polymorphisms in the cannabinoid receptor gene (CNR1) and impulsivity in southwest California Indians. Twin Res. Hum. Genet. 2007, 10(6):805-811.
23. Feng Q., Jiang L., Berg R.L., Antonik M., MacKinney E., Gunnell-Santoro J., McCarty C.A., Wilke R.A. A common CNR1 (cannabinoid receptor 1) haplotype attenuates the decrease in HDL cholesterol that typically accompanies weight gain. PLoS One 2010, 5(12):e15779.
24. Frost M., Nielsen T.L., Wraae K., Hagen C., Piters E., Beckers S., De Freitas F., Brixen K., Van Hul W., Andersen M. Polymorphisms in the endocannabinoid receptor 1 in relation to fat mass distribution. Eur. J. Endocrinol. 2010, 163(3):407-412.
25. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Le Fur G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 1995, 232(1):54-61.
26. Gamber K.M., Macarthur H., Westfall T.C. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology 2005, 49(5):646-652.
27. Harris G., Andreasen N.C., Cizadlo T., Bailey J.M., Bockholt H.J., Magnotta V.A., Arndt S. Improving tissue classification in MRI: a three-dimensional multispectral discriminant analysis method with automated training class selection. J. Comput. Assist. Tomogr. 1999, 23(1):144-154.
28. Haughey H.M., Marshall E., Schacht J.P., Louis A., Hutchison K.E. Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes. Addiction 2008, 103(10):1678-1686.
29. Hirvonen J., Zanotti-Fregonara P., Umhau J.C., George D.T., Rallis-Frutos D., Lyoo C.H., Li C.T., Hines C.S., Sun H., Terry G.E., Morse C., Zoghbi S.S., Pike V.W., Innis R.B., Heilig M. Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography. Mol. Psychiatry 2013, 18(8):916-921.
30. Kuliczkowska Plaksej J., Laczmanski L., Milewicz A., Lenarcik-Kabza A., Trzmiel-Bira A., Zaleska-Dorobisz U., Lwow F., Hirnle L. Cannabinoid receptor 1 gene polymorphisms and nonalcoholic Fatty liver disease in women with polycystic ovary syndrome and in healthy controls. Int. J. Endocrinol. 2014, 2014:232975.
31. Lawrie S.M., McIntosh A.M., Hall J., Owens D.G., Johnstone E.C. Brain structure and function changes during the development of schizophrenia: the evidence from studies of subjects at increased genetic risk. Schizophr. Bull. 2008, 34(2):330-340.
32. Lenarcik-Kabza A., Laczmanski L., Milewicz A., Bidzinska-Speichert B., Pawlak M., Kolackov K., Kuliczkowska-Plaksej J., Trzmiel-Bira A., Brona A. The influence of endocannabinoid receptor 1 gene variations on anthropometric and metabolic parameters of women with polycystic ovary syndrome. Endokrynol. Pol. 2014, 65(3):181-188.
33. Lewis C.M., Levinson D.F., Wise L.H., DeLisi L.E., Straub R.E., Hovatta I., Williams N.M., Schwab S.G., Pulver A.E., Faraone S.V., Brzustowicz L.M., Kaufmann C.A., Garver D.L., Gurling H.M., Lindholm E., Coon H., Moises H.W., Byerley W., Shaw S.H., Mesen A., Sherrington R., O'Neill F.A., Walsh D., Kendler K.S., Ekelund J., Paunio T., Lonnqvist J., Peltonen L., O'Donovan M.C., Owen M.J., Wildenauer D.B., Maier W., Nestadt G., Blouin J.L., Antonarakis S.E., Mowry B.J., Silverman J.M., Crowe R.R., Cloninger C.R., Tsuang M.T., Malaspina D., Harkavy-Friedman J.M., Svrakic D.M., Bassett A.S., Holcomb J., Kalsi G., McQuillin A., Brynjolfson J., Sigmundsson T., Petursson H., Jazin E., Zoega T., Helgason T. Genome scan meta-analysis of schizophrenia and bipolar disorder. Part II: schizophrenia. Am. J. Hum. Genet. 2003, 73(1):34-48.
34. Lou Z.Y., Zhao C.B., Xiao B.G. Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist. J. Neurosci. Res. 2012, 90(1):84-95.
35. Martinez-Gras I., Hoenicka J., Ponce G., Rodriguez-Jimenez R., Jimenez-Arriero M.A., Perez-Hernandez E., Ampuero I., Ramos-Atance J.A., Palomo T., Rubio G. (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population. Eur. Arch. Psychiatry Clin. Neurosci. 2006, 256(7):437-441.
36. Mata I., Perez-Iglesias R., Roiz-Santianez R., Tordesillas-Gutierrez D., Gonzalez-Mandly A., Berja A., Vazquez-Barquero J.L., Crespo-Facorro B. Additive effect of NRG1 and DISC1 genes on lateral ventricle enlargement in first episode schizophrenia. Neuroimage 2010, 53(3):1016-1022.
37. Milewicz A., Tworowska-Bardzinska U., Jedrzejuk D., Lwow F., Dunajska K., Laczmanski L., Pawlak M. Are endocannabinoid type 1 receptor gene (CNR1) polymorphisms associated with obesity and metabolic syndrome in postmenopausal Polish women?. Int. J. Obes. 2011, 35(3):373-377.
38. Mitjans M., Serretti A., Fabbri C., Gasto C., Catalan R., Fananas L., Arias B. Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. Psychopharmacology (Berl) 2013, 227(3):509-519.
39. Monteleone P., Bifulco M., Maina G., Tortorella A., Gazzerro P., Proto M.C., Di Filippo C., Monteleone F., Canestrelli B., Buonerba G., Bogetto F., Maj M. Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol. Res. 2010, 61(5):400-404.
40. Muller T.D., Reichwald K., Wermter A.K., Bronner G., Nguyen T.T., Friedel S., Koberwitz K., Engeli S., Lichtner P., Meitinger T., Schafer H., Hebebrand J., Hinney A. No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents. Mol. Genet. Metab. 2007, 90(4):429-434.
41. Okahisa Y., Kodama M., Takaki M., Inada T., Uchimura N., Yamada M., Iwata N., Iyo M., Sora I., Ozaki N., Ujike H. Association study of two cannabinoid receptor genes, CNR1 and CNR2, with methamphetamine dependence. Curr. Neuropharmacol. 2011, 9(1):183-189.
42. Onaivi E.S. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. Int. Rev. Neurobiol. 2009, 88:335-369.
43. Onaivi E.S., Ishiguro H., Gu S., Liu Q.R. CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J. Psychopharmacol. 2012, 26(1):92-103.
44. Onwuameze O.E., Nam K.W., Epping E.A., Wassink T.H., Ziebell S., Andreasen N.C., Ho B.C. MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse. Psychol. Med. 2013, 43(3):619-631.
45. Overall J.E., Gorham D.R. The brief psychiatric report scale. Psychol. Rep. 1962, 10:799-812.
46. Perkins D.O., Gu H., Boteva K., Lieberman J.A. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am. J. Psychiatry 2005, 162(10):1785-1804.
47. Pertwee R.G. Cannabinoid pharmacology: the first 66 years. Br. J. Pharmacol. 2006, 147(Suppl. 1):S163-S171.
48. PGC-SCZ Schizophrenia working group of the psychiatric genomics consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511(7510):421-427.
49. Quickfall J., Crockford D. Brain neuroimaging in cannabis use: a review. J. Neuropsychiatry Clin. Neurosci. 2006, 18(3):318-332.
50. Rais M., Cahn W., Van Haren N., Schnack H., Caspers E., Hulshoff Pol H., Kahn R. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am. J. Psychiatry 2008, 165(4):490-496.
51. Ripke S., O'Dushlaine C., Chambert K., Moran J.L., Kahler A.K., Akterin S., Bergen S.E., Collins A.L., Crowley J.J., Fromer M., Kim Y., Lee S.H., Magnusson P.K., Sanchez N., Stahl E.A., Williams S., Wray N.R., Xia K., Bettella F., Borglum A.D., Bulik-Sullivan B.K., Cormican P., Craddock N., de Leeuw C., Durmishi N., Gill M., Golimbet V., Hamshere M.L., Holmans P., Hougaard D.M., Kendler K.S., Lin K., Morris D.W., Mors O., Mortensen P.B., Neale B.M., O'Neill F.A., Owen M.J., Milovancevic M.P., Posthuma D., Powell J., Richards A.L., Riley B.P., Ruderfer D., Rujescu D., Sigurdsson E., Silagadze T., Smit A.B., Stefansson H., Steinberg S., Suvisaari J., Tosato S., Verhage M., Walters J.T., Levinson D.F., Gejman P.V., Laurent C., Mowry B.J., O'Donovan M.C., Pulver A.E., Schwab S.G., Wildenauer D.B., Dudbridge F., Shi J., Albus M., Alexander M., Campion D., Cohen D., Dikeos D., Duan J., Eichhammer P., Godard S., Hansen M., Lerer F.B., Liang K.Y., Maier W., Mallet J., Nertney D.A., Nestadt G., Norton N., Papadimitriou G.N., Ribble R., Sanders A.R., Silverman J.M., Walsh D., Williams N.M., Wormley B., Arranz M.J., Bakker S., Bender S., Bramon E., Collier D., Crespo-Facorro B., Hall J., Iyegbe C., Jablensky A., Kahn R.S., Kalaydjieva L., Lawrie S., Lewis C.M., Linszen D.H., Mata I., McIntosh A., Murray R.M., Ophoff R.A., Van Os J., Walshe M., Weisbrod M., Wiersma D., Donnelly P., Barroso I., Blackwell J.M., Brown M.A., Casas J.P., Corvin A.P., Deloukas P., Duncanson A., Jankowski J., Markus H.S., Mathew C.G., Palmer C.N., Plomin R., Rautanen A., Sawcer S.J., Trembath R.C., Viswanathan A.C., Wood N.W., Spencer C.C., Band G., Bellenguez C., Freeman C., Hellenthal G., Giannoulatou E., Pirinen M., Pearson R.D., Strange A., Su Z., Vukcevic D., Langford C., Hunt S.E., Edkins S., Gwilliam R., Blackburn H., Bumpstead S.J., Dronov S., Gillman M., Gray E., Hammond N., Jayakumar A., McCann O.T., Liddle J., Potter S.C., Ravindrarajah R., Ricketts M., Tashakkori-Ghanbaria A., Waller M.J., Weston P., Widaa S., Whittaker P., McCarthy M.I., Stefansson K., Scolnick E., Purcell S., McCarroll S.A., Sklar P., Hultman C.M., Sullivan P.F. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat. Genet. 2013, 45(10):1150-1159.
52. Ross C.A., Margolis R.L., Reading S.A., Pletnikov M., Coyle J.T. Neurobiology of schizophrenia. Neuron 2006, 52(1):139-153.
53. Rossi S., Bozzali M., Bari M., Mori F., Studer V., Motta C., Buttari F., Cercignani M., Gravina P., Mastrangelo N., Castelli M., Mancino R., Nucci C., Sottile F., Bernardini S., Maccarrone M., Centonze D. Association between a genetic variant of type-1 cannabinoid receptor and inflammatory neurodegeneration in multiple sclerosis. PLoS One 2013, 8(12):e82848.
54. Schacht J.P., Hutchison K.E., Filbey F.M. Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users. Neuropsychopharmacology 2012, 37(11):2368-2376.
55. Seifert J., Ossege S., Emrich H.M., Schneider U., Stuhrmann M. No association of CNR1 gene variations with susceptibility to schizophrenia. Neurosci. Lett. 2007, 426(1):29-33.
56. Simons C.J., Wichers M., Derom C., Thiery E., Myin-Germeys I., Krabbendam L., van Os J. Subtle gene-environment interactions driving paranoia in daily life. Genes Brain Behav 2009, 8(1):5-12.
57. Skaper S.D., Di Marzo V. Endocannabinoids in nervous system health and disease: the big picture in a nutshell. Philos. Trans. R. Soc. B: Biol. Sci. 2012, 367(1607):3193-3200.
58. Spitzer R.W., Gibbon M, MEB F. Structured Clinical Interview for DSM-III-R 1990, American Psychiatric Press, Washington, DC.
59. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., Werge T., Pietilainen O.P., Mors O., Mortensen P.B., Sigurdsson E., Gustafsson O., Nyegaard M., Tuulio-Henriksson A., Ingason A., Hansen T., Suvisaari J., Lonnqvist J., Paunio T., Borglum A.D., Hartmann A., Fink-Jensen A., Nordentoft M., Hougaard D., Norgaard-Pedersen B., Bottcher Y., Olesen J., Breuer R., Moller H.J., Giegling I., Rasmussen H.B., Timm S., Mattheisen M., Bitter I., Rethelyi J.M., Magnusdottir B.B., Sigmundsson T., Olason P., Masson G., Gulcher J.R., Haraldsson M., Fossdal R., Thorgeirsson T.E., Thorsteinsdottir U., Ruggeri M., Tosato S., Franke B., Strengman E., Kiemeney L.A., Melle I., Djurovic S., Abramova L., Kaleda V., Sanjuan J., de Frutos R., Bramon E., Vassos E., Fraser G., Ettinger U., Picchioni M., Walker N., Toulopoulou T., Need A.C., Ge D., Yoon J.L., Shianna K.V., Freimer N.B., Cantor R.M., Murray R., Kong A., Golimbet V., Carracedo A., Arango C., Costas J., Jonsson E.G., Terenius L., Agartz I., Petursson H., Nothen M.M., Rietschel M., Matthews P.M., Muglia P., Peltonen L., St Clair D., Goldstein D.B., Stefansson K., Collier D.A. Common variants conferring risk of schizophrenia. Nature 2009, 460(7256):744-747.
60. Tiwari A.K., Zai C.C., Likhodi O., Voineskos A.N., Meltzer H.Y., Lieberman J.A., Potkin S.G., Remington G., Muller D.J., Kennedy J.L. Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. Pharmacogenomics J. 2012, 12(3):260-266.
61. Tobler A.R., Short S., Andersen M.R., Paner T.M., Briggs J.C., Lambert S.M., Wu P.P., Wang Y., Spoonde A.Y., Koehler R.T., Peyret N., Chen C., Broomer A.J., Ridzon D.A., Zhou H., Hoo B.S., Hayashibara K.C., Leong L.N., Ma C.N., Rosenblum B.B., Day J.P., Ziegle J.S., De La Vega F.M., Rhodes M.D., Hennessy K.M., Wenz H.M. The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping. J. Biomol. Tech. 2005, 16(4):398-406.
62. Torrey E.F., Bartko J.J., Yolken R.H. Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr. Bull. 2012, 38(3):642-647.
63. Ujike H., Morita Y. New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J. Pharmaceutical Sciences 2004, 96(4):376-381.
64. Ujike H., Takaki M., Nakata K., Tanaka Y., Takeda T., Kodama M., Fujiwara Y., Sakai A., Kuroda S. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol. Psychiatry 2002, 7(5):515-518.
65. van Os J., Krabbendam L., Myin-Germeys I., Delespaul P. The schizophrenia envirome. Curr. Opin. Psychiatry 2005, 18(2):141-145.
66. Vonesh E.F., Chinchilli V.M., Pu K. Goodness-of-fit in generalized nonlinear mixed-effects models. Biometrics 1996, 52(2):572-587.
67. 11C]OMAR. Neuroimage 2010, 52(4):1505-1513.
68. Woods B.T. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am. J. Psychiatry 1998, 155(12):1661-1670.
69. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64(6):663-667.
70. Yu W., De Hert M., Moons T., Claes S.J., Correll C.U., van Winkel R. CNR1 gene and risk of the metabolic syndrome in patients with schizophrenia. J. Clin. Psychopharmacol. 2013, 33(2):186-192.
71. Zavitsanou K., Dalton V.S., Walker A.K., Weickert C.S., Sominsky L., Hodgson D.M. Neonatal lipopolysaccharide treatment has long-term effects on monoaminergic and cannabinoid receptors in the rat. Synapse 2013, 67(6):290-299.
72. Zhuang M., Yang Y., Cao F., Lu M., Wang X., Zhang J., Chen X., Cheng P., Zhang N., Ye W., Jin L. Associations of variants of CNR1 with obesity and obesity-related traits in Chinese women. Gene 2012, 495(2):194-198.
73. Ziats M.N., Rennert O.M. Expression profiling of autism candidate genes during human brain development implicates central immune signaling pathways. PLoS One 2011, 6(9):e24691.
74. Ziegler A., Inke R., Friedrich P. A Statistical Approach to Genetic Epidemiology: Concepts and Applications 2010, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.